Skip to main content
. Author manuscript; available in PMC: 2023 Apr 15.
Published in final edited form as: J Acquir Immune Defic Syndr. 2023 Apr 15;92(5):422–429. doi: 10.1097/QAI.0000000000003157

Table 2. Viral load outcomes at week 24, 48 and 72.

VL suppression <50copies/mL
(n; percentage, 95% CI)		 VL suppression <400copies/mL
(n; percentage, 95% CI)
mITT analysis* Sensitivity
analysis** 		mITT analysis* Sensitivity
analysis**
Week 24 53/62;
85 (74-93)		 53/60;
88 (77-95)		 59/62;
95 (87-99)		 59/60;
98 (91-100)
Week 48 45/61;
74 (61-84)		 45/57;
79 (66-89)		 51/61;
84 (72-92)		 51/57;
89 (78-96)
Week 72 46/61;
75 (63-86)		 46/55
84 (71-92)		 47/61;
77 (65-87)		 47/55
85 (73-94)
*

Modified intention-to-treat analysis (mITT) excludes those switching study drug for reasons of stopping contraception or wish to become pregnant, or becoming pregnant, transfer out for non-clinical reasons and death from non-HIV and non-drug causes.

**

Sensitivity analysis excludes those excluded from mITT analysis, as well as those lost to follow up, those missing a VL within the window and participants who stopped or were changed from the study drug for reasons other than failure of the regimen